We use cookies to personalise content and ads, to provide social media features and to analyse traffic. We share info about use of our site with social media, ads and analytics partners. By continuing to browse you are agreeing to use of cookies.
See details or close this message.
Page
/14
100%
Specifications
A View from the Top HASSALLR
Business section
Specifications
A View from the Top HASSALLR
Outline
Center Director’s Update Outline Generic Drug Review Continues to Be Critical Priority for CDER Revision of “First-In, First-Reviewed Policy” CDER/OGD Initiatives Critical Path for Generic Products Regarding Complex Drug Substances IOM Study Impact Enhancements Already in Place Challenges Citizen Petitions Resources Future of OGD
Suggested Link Details/Purchase
Content
Center Director’s Update Steven Galson, M.D., M.P.H. Director Center for Drug Evaluation and Research